Lucinactant for the prevention of respiratory distress syndrome in premature infants

Brian K. Jordan, Steven M. Donn

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Respiratory distress syndrome (RDS) is the leading cause of neonatal morbidity and mortality in premature infants. It is caused by surfactant deficiency and lung immaturity. Lucinactant is a synthetic surfactant containing sinapultide, a bioengineered peptide mimic of surfactant-associated protein B. A meta-analysis of clinical trials demonstrates that lucinactant is as effective as animal-derived surfactants in preventing RDS in premature neonates, and in vitro studies suggest it is more resistant to oxidative and protein-induced inactivation. Its synthetic origin confers lower infection and inflammation risks as well other potential benefits, which may make lucinactant an advantageous alternative to its animal-derived counterparts, which are presently the standard treatment for RDS.

Original languageEnglish (US)
Pages (from-to)115-121
Number of pages7
JournalExpert Review of Clinical Pharmacology
Volume6
Issue number2
DOIs
StatePublished - Mar 2013
Externally publishedYes

Keywords

  • lucinactant
  • prematurity
  • respiratory distress syndrome
  • sinapultide
  • surfactant

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Lucinactant for the prevention of respiratory distress syndrome in premature infants'. Together they form a unique fingerprint.

Cite this